# Narcolepsy

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred                     | Generic Name | Quantity | Time (Days) |
| :---------------------------- | :----------- | :------: | :---------: |
| Amphetamine/Dextroamphetamine |              |          |             |
| Armodafinil                   |              |          |             |
| Dextroamphetamine ER          |              |          |             |
| Methylphenidate ER            |              |          |             |
| Methylphenidate Tab           |              |          |             |
| Modafinil                     |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Sunosi        |              |          |             |
| Wakix         |              |          |             |
| Xyrem         |              |          |             |
| Xywav         |              |          |             |

## Length of Authorizations

365 Days

## Prior Authorization Criteria

Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:

-   Allergy to medications not requiring prior approval
-   Contraindications to or drug interaction with medications not requiring prior approval
-   History of unacceptable/toxic side effects to medications not requiring prior approval

## Additional Criteria

### Non-Preferred

-   For non‐preferred drugs without medication specific criteria, there must have been an inadequate clinical response to preferred alternatives, including a trial of no less than 30 days each of at least two preferred products

### Sunosi (soriamfetol)

-   Diagnosis of narcolepsy with excessive daytime sleepiness or obstructive sleep apnea with excessive daytime sleepiness **AND**
-   An inadequate response to or inability to tolerate a 30-day course of treatment with modafinil or armodafinil **AND**
-   An inadequate response to or inability to tolerate a 30-day course of treatment with a preferred methylphenidate or amphetamine product

### Wakix (pitolisant), Xyrem (sodium oxybate)

-   Diagnosis of narcolepsy with excessive daytime sleepiness **AND**
-   An inadequate response to or inability to tolerate a 30‐day course of treatment with modafinil or armodafinil **AND**
-   An inadequate response to or inability to tolerate a 30‐day course of treatment with a preferred methylphenidate or amphetamine product **OR**
-   Diagnosis of narcolepsy with cataplexy

### Xywav (calcium, magnesium, potassium & sodium oxybates)

-   Diagnosis of narcolepsy with excessive daytime sleepiness **AND**
-   An inadequate response to or inability to tolerate a 30‐day course of treatment with modafinil or armodafinil **AND**
-   An inadequate response to or inability to tolerate a 30‐day course of treatment with a preferred methylphenidate or amphetamine product **AND**
-   Sodium restriction with documented adherence to sodium restricted diet **OR**
-   Diagnosis of narcolepsy with cataplexy **AND**
-   Sodium restriction with documented adherence to sodium restricted diet

### Reauthorization

Attestation that the patient’s condition has improved while taking the requested medication

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=39)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=16)
